Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Deferred Revenue (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Deferred Revenue for 14 consecutive years, with $14000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 77.05% to $14000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14000.0 through Dec 2025, down 77.05% year-over-year, with the annual reading at $14000.0 for FY2025, 77.05% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $14000.0 at Gyre Therapeutics, down from $58000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $2.0 million in Q2 2021, with the low at $14000.0 in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $378923.1, with a median of $58000.0 recorded in 2025.
  • Peak annual rise in Current Deferred Revenue hit 517.58% in 2021, while the deepest fall reached 88.4% in 2021.
  • Over 5 years, Current Deferred Revenue stood at $230000.0 in 2021, then plummeted by 36.96% to $145000.0 in 2022, then crashed by 73.1% to $39000.0 in 2023, then soared by 56.41% to $61000.0 in 2024, then plummeted by 77.05% to $14000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $14000.0, $58000.0, and $28000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.